

First Quarter Report

as of March 31, 2007

April 25, 2007



Highlights Q1 2007

- 1) Placebo-controlled phase IIa study with hypertension vaccine CYT006-AngQb showed reduction in day-time ambulatory blood pressure.
- 2) Placebo-controlled phase IIa study with CYT003-QbG10 monotherapy showed significant improvement of allergy symptoms in hay fever patients.
- 3) Excellent 18 months follow-up results in phase IIa study for house dust mite allergy confirmed long-term treatment effect of CYT003-QbG10 in combination with allergen.
- 4) Cytos Biotechnology has successfully placed a Convertible Bond of CHF 70 million.
- 5) Financial summary:

		Q1 2007	Q1 2006
Net revenue	CHF mio	0.2	0.2
Net operating costs	CHF mio	8.8	8.8
Net loss	CHF mio	5.7	8.4

		March 31, 2007	Dec 31, 2006
Cash & cashable assets ¹⁾	CHF mio	99.4	44.5
Full-time employees	number	129	127

1) including cash and cash equivalents, short-term and long-term financial assets and real estate inventories

1) Placebo-controlled phase IIa study with hypertension vaccine CYT006-AngQb showed reduction in day-time ambulatory blood pressure

In January 2007, Cytos Biotechnology reported positive results from a phase IIa study with CYT006-AngQb, a therapeutic vaccine to treat high blood pressure. The study was a double-blind, placebo-controlled clinical trial conducted in 72 participants with mild to moderate hypertension. It was designed to evaluate the safety, tolerability, and exploratory efficacy of two dose levels of the vaccine (100 µg and 300 µg). For efficacy evaluation, the change in blood pressure from baseline to post-treatment was assessed in individual subjects by 24-hour ambulatory blood pressure monitoring.

Treatment with CYT006-AngQb was safe and very well tolerated. All patients who received the vaccine mounted a strong antibody response against angiotensin II after the very first injection, which was boosted by the two subsequent injections. The antibody response was long-lived with a half-life of 3-4 months.

A significant reduction of ambulatory day-time blood pressure was observed in the group who received the 300 µg dose of the vaccine (i.e. reduction of systolic blood pressure by 5.5 mmHg; diastolic blood pressure by 2.8 mmHg). This reduction is in the range of what one can expect with low doses of small molecule inhibitors of the renin-angiotensin system in the same setting using ambulatory blood pressure monitoring. When comparing the reduction in day-time ambulatory systolic blood pressure to placebo, the difference obtained was also significant. As expected, during night-time, when the blood pressure is lower, differences were smaller and non-significant. These positive data provide a sound rationale for the further development of this very promising vaccine candidate.

2) Placebo-controlled phase IIa study with CYT003-QbG10 monotherapy showed significant improvement of allergy symptoms in hay fever patients

In March 2007, Cytos Biotechnology reported positive results from a phase IIa study with CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. The study included 40 patients suffering from mild to moderate allergic rhinitis due to grass pollen allergy (hay fever). The trial investigated in a double-blind setting the safety, tolerability and exploratory efficacy of two different formulations of CYT003-QbG10 monotherapy to placebo, and in an open-label setting a CYT003-QbG10 formulation comprising a low dose of grass pollen extract. Exploratory efficacy of CYT003-QbG10 was determined by assessing the allergic disease status of the patients before and after treatment by the conjunctival provocation test, yielding a symptom score ranging from 0 to 15 points.

All formulations of CYT003-QbG10 tested were safe and well tolerated. Treatment with CYT003-QbG10 monotherapy led to a significant improvement of allergy symptoms in the conjunctival provocation test when compared to placebo.

bo. A reduction of the median symptom score from 9 points pre-treatment to 5 points post-treatment was achieved (for placebo: 9 points pre-treatment to 8 points post-treatment). For the formulation of CYT003-QbG10 plus grass pollen extract, the median symptom score was reduced from 9 points pre-treatment to 4 points post-treatment, whereas for the formulation of CYT003-QbG10 plus alum, no significant reduction was observed when compared to placebo.

These results mark a further important milestone in the development of CYT003-QbG10 monotherapy as a causal and disease-modifying therapy for a broad range of allergic diseases. Several clinical trials are currently ongoing to further assess various parameters of this promising Immunodrug™ candidate such as different formulations, doses, and treatment regimens.

3) Excellent 18 months follow-up results in phase IIa study for house dust mite allergy confirmed long-term treatment effect of CYT003-QbG10 in combination with allergen

In March 2007, Cytos Biotechnology obtained 18 months follow-up results from a phase IIa study conducted in 20 patients with allergic rhinitis and asthma due to house dust mite allergy. The study assessed safety, tolerability and exploratory efficacy of CYT003-QbG10 in combination with a house dust mite extract (study drug designated CYT005-AllQbG10). Cytos Biotechnology has previously reported about the sustained efficacy of CYT005-AllQbG10 achieved after 3, 8 and 12 months (see press releases December 14, 2005 and April 25, 2006, and Q3 report 2006).

The results obtained 18 months after the start of treatment further confirmed the long-lasting therapeutic effect induced by the immunotherapeutic. At the follow-up visit, the allergic status of the patients was recorded by the conjunctival provocation test. In this test, the median allergen tolerance remained still increased by a factor of 100 ($p < 0.0001$) and thus tallied the results obtained earlier. Also allergic rhinitis and asthma in daily life remained significantly improved as well as the consequences of the disease, which described restrictions due to the disease during work, leisure time, or sleep.

These positive results provide a solid understanding of the long-term efficacy for this Immunodrug™ candidate and will be very valuable for ongoing and future development activities towards a novel allergy immunotherapeutic.

4) Cytos Biotechnology has successfully placed a convertible bond of CHF 70 million

In February 2007, Cytos Biotechnology has successfully placed a convertible bond of CHF 70 million due 2012. The funds will be used to accelerate development of further promising Immunodrug™ candidates in the pipeline and to increase the financial flexibility of Cytos Biotechnology. The conditions of the convertible bond comprise a coupon of 2.875% per annum and a conversion price of CHF 175, representing a conversion premium of 34.25%. The maturity date is February 20, 2012. The shares will be issued out of the conditional capital of Cytos Biotechnology. The convertible bond has been listed on the SWX Swiss Exchange since February 16, 2007.

5) Financial results

Cash and cashable assets increased to CHF 99.4 million as of March 31, 2007, in comparison to CHF 44.5 million at the end of December 2006. This increase is attributable to the issuance of the convertible bond.

Revenues remained with CHF 0.2 million in the first quarter 2007 on the same level as in the first quarter 2006.

Net operating costs in the first quarter 2007 amounted to CHF 8.8 million and were stable compared to the first quarter 2006, when taking into account that other income increased by CHF 1.0 million to CHF 1.1 million due to the sale of properties in Belp in the first quarter 2007.

Research and development costs increased by CHF 0.9 million to CHF 8.7 million due to extended activities in product development, while sales and marketing and general and administrative costs remained stable.

As a consequence of the issuance of the convertible bond, financial expenses increased to CHF 0.5 million.

Net loss in the first quarter 2007 decreased by CHF 2.7 million in comparison to the first quarter 2006 and amounted to CHF 5.7 million. This decrease arises out of recognizing non-cash deferred taxes of CHF 3.0 million as described in note 10.

The gross cash burn for operating activities as calculated based on the Cash Flow Statement was CHF 4.2 million per month in the first three months 2007, compared to CHF 2.4 million per month in the first three months 2006. The burn rate in the first quarter 2007 included a prepayment of CHF 1.5 million for the full year pension fund liability, so that by omitting this pension fund payment the monthly burn rate would have been CHF 3.7 million.

Glossary

Allergen: a normally harmless substance that elicits a misdirected immune response.

Allergen extract: a mixture of allergenic components such as from house dust mites or grass pollen.

Allergen tolerance: non-reactivity to a certain allergen or reactivity only up to the level of a predefined minimal symptom score.

Allergic rhinitis: a condition due to allergy that mimics a cold. "Rhinitis" means inflammation of the nasal mucous membranes.

Alum: a certain adjuvant. Commonly used in human application to enhance an immune response.

Ambulatory blood pressure monitoring: takes numerous readings of the blood pressure over a 24-hour period or longer.

Angiotensin II: small peptide that is part of the renin-angiotensin system. Induces narrowing of blood vessels and other effects to raise blood pressure.

Antibody: class of blood proteins generated by the immune system to bind and neutralize foreign materials (e.g. bacteria or viruses). Can also be directed against the body's own disease-relevant molecules (e.g. angiotensin II).

Asthma: a chronic inflammatory disorder of the airways leading to recurrent episodes of wheezing, breathlessness, chest tightness and cough in susceptible individuals.

Conjunctival provocation test: a test procedure that records allergic symptoms upon defined allergen exposure to determine the allergic disease status of a patient.

Diastolic blood pressure: lowest pressure within the arterial blood stream occurring during each heart beat. Blood pressure values are given in millimetres of mercury (mmHg).

Disease-modifying: in contrast to symptomatic treatment, a disease-modifying treatment aims at addressing the cause of disease and modifying the disease progression.

Double-blind: a set-up used in clinical trials where neither the doctor nor the patient knows if placebo or the active drug substance is applied.

Formulation: method and process of selecting the components of a mixture and the product of such a process. For drugs the term usually describes the final way a drug is prepared.

Half-life: time required for half the amount of a certain substance (e.g. antibodies) to be removed from the organism.

Hay fever: seasonal allergic rhinitis.

Hypertension: high blood pressure.

Immunotherapeutic: a product aimed at activation of the immune system to interfere with and modify a certain disease process.

Median: a term used in the statistical analysis of a set of numbers; it relates to or constitutes the middle value in a distribution. 50% of the values are above and 50% below the median.

Monotherapy: treatment with one drug as opposed to combination therapy. Here the term refers to treatment with QbG10 alone (designated as CYT003-QbG10) in contrast to a treatment regimen where QbG10 was combined to an allergen extract of house dust mites (designated as CYT005-AllQbG10).

Open-label: set-up used in clinical trials where the doctor and the patient know if the active drug or placebo is administered.

Phase IIa: a clinical trial that examines a new drug candidate's safety, tolerability and exploratory efficacy in the targeted population and may involve 10-100 patients.

Placebo: dummy medical treatment.

QbG10: Cytos Biotechnology's Immunodrug™ Qb filled with the synthetically produced immunostimulatory DNA sequence G10.

Regimen: describes the schedule and composition according to which a drug is administered.

Renin-angiotensin system: important regulatory system of blood pressure.

Systolic blood pressure: highest pressure within the arterial blood stream occurring during each heart beat. Blood pressure values are given in millimetres of mercury (mmHg).

Therapeutic vaccine: preparation of disease-relevant molecules (i.e. antigens) that is capable of activating the immune system against such antigens with the goal of modifying and interfering with a certain disease process.

Cytos Biotechnology AG and subsidiaries

Consolidated Balance Sheet as of in TCHF	Note	March 31, 2007	December 31, 2006
Current assets:			
Cash and cash equivalents		20,513	9,149
Financial assets	7	55,000	18,000
Trade and other receivables		2,648	845
Real estate inventories	9	12,844	14,124
Prepayments		5,147	2,378
Total current assets		96,152	44,496
Long-term assets:			
Property and equipment, net	8	12,209	12,575
Financial assets	7	10,000	0
Pension assets		310	310
Investment in associates		31	31
Total long-term assets		22,550	12,916
Total assets		118,702	57,412
Current liabilities:			
Trade accounts payable		2,628	3,008
Loans payable	7	-	132
Other current liabilities		812	664
Accrued expenses		5,465	4,590
Provisions		150	157
Total current liabilities		9,055	8,551
Long-term liabilities:			
Loans payable	7	-	1,088
Convertible bond	10	56,855	-
Provisions		1,884	1,873
Total long-term liabilities		58,739	2,961
Shareholders' equity:			
Share capital	3	520	517
Legal reserves		136	136
Additional paid-in capital		200,038	197,684
Convertible bond – equity component	10	8,429	-
Treasury shares		(109)	(46)
Accumulated deficit		(158,106)	(152,391)
Total shareholders' equity		50,908	45,900
Total liabilities and shareholders' equity		118,702	57,412

See accompanying notes which are an integral part of these consolidated condensed interim financial statements.

Cytos Biotechnology AG and subsidiaries

Consolidated Income Statement		Three months ended	Three months ended
in TCHF (except for share information)	Note	March 31, 2007	March 31, 2006
Research and collaboration revenues	4	197	163
Total revenues		197	163
Research and development		(8,668)	(7,784)
Sales and marketing		(215)	(222)
General and administrative		(944)	(902)
Other income/(expenses), net		1,069	149
Net operating costs		(8,758)	(8,759)
Operating loss		(8,561)	(8,596)
Financial income		318	201
Financial expense		(464)	(25)
Loss before tax		(8,707)	(8,420)
Deferred tax income convertible bond	10	2,992	-
Net loss		(5,715)	(8,420)
Basic and diluted net loss per share	5	(1.10)	(1.65)
Weighted average number of shares used in computing basic and diluted net loss per share		5,196,316	5,113,729
<i>See accompanying notes which are an integral part of these consolidated condensed interim financial statements.</i>			

Cytos Biotechnology AG and subsidiaries

Consolidated Statement of Cash Flows in TCHF	Note	Three months ended March 31, 2007	Three months ended March 31, 2006
Cash flow from operating activities:			
Loss before tax		(8,707)	(8,420)
Depreciation and amortization		703	689
Share option compensation cost	6	664	722
Outflow for cash settled options		(422)	-
Other financial cash-flow items		(953)	(193)
Changes in assets and liabilities		(3,589)	42
Net cash (used in)/provided by operating activities		(12,304)	(7,160)
Net cash (used in)/provided by investing activities		(44,867)	8,127
Net cash (used in)/provided by financing activities		68,528	1,750
Net effect of currency translation on cash		7	0
Net increase/(decrease) in cash and cash equivalents		11,364	2,717
Cash and cash equivalents, beginning of period		9,149	11,469
Cash and cash equivalents, end of period		20,513	14,186
<i>See accompanying notes which are an integral part of these consolidated condensed interim financial statements.</i>			

Consolidated Statement of Change in Shareholders' Equity

in TCHF (except for share information)

	Numbers of shares	Share capital	Legal reserves	Additional paid-in capital	Convertible bond - equity component	Treasury shares	Accumulated deficit	Cumulative translation adjustments	Total
January 1, 2006	5,086,993	509	136	191,506	-	(298)	(117,622)	(220)	74,011
Net income/(expense) recognized directly in equity	-	-	-	-	-	-	-	1	1
Loss for the year	-	-	-	-	-	-	(8,420)	-	(8,420)
Total recognized loss									(8,419)
Issuance of share capital	42,724	4	-	1,713	-	-	-	-	1,717
Net movement of treasury shares	-	-	-	254	-	(190)	-	-	64
Share option compensation cost	-	-	-	413	-	-	-	-	413
March 31, 2006	5,129,717	513	136	193,886	-	(488)	(126,042)	(219)	67,786
January 1, 2007	5,174,188	517	136	197,684	-	(46)	(152,174)	(217)	45,900
Net income/(expense) recognized directly in equity	-	-	-	-	-	-	-	-	-
Loss for the year	-	-	-	-	-	-	(5,715)	-	(5,715)
Total recognized loss									(5,715)
Issuance of share capital	27,930	3	-	1,705	-	-	-	-	1,708
Issuance of convertible bond - equity component	-	-	-	-	11,788	-	-	-	11,788
Transaction costs - convertible bond (allocation to equity)	-	-	-	-	(367)	-	-	-	(367)
Deferred tax - convertible bond	-	-	-	-	(2,992)	-	-	-	(2,992)
Net movement of treasury shares	-	-	-	79	-	(63)	-	-	16
Share option compensation cost	-	-	-	570	-	-	-	-	570
March 31, 2007	5,202,118	520	136	200,038	8,429	(109)	(157,889)	(217)	50,908

See accompanying notes which are an integral part of these consolidated condensed interim financial statements.

1) Organization

Cytos Biotechnology AG (the "Company"), a public Swiss biotechnology company, and its subsidiaries (together the "Group") specialize in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of chronic diseases and aim at triggering the patient's immune system to induce specific antibody and targeted T cell responses to modulate chronic disease processes.

2) Basis of preparation

These consolidated condensed interim financial statements are prepared in accordance with IAS 34 "Interim Financial Reporting". The accounting policies used in the preparation of the interim financial statements are consistent with those used in the annual financial statements for the year ended December 31, 2006.

These consolidated condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended December 31, 2006.

For better readability the amounts in the Group's financial statements and notes are presented in thousand Swiss Francs (TCHF) unless stated otherwise.

3) Shareholders' equity

On March 26, 2007, the board of directors registered an increase of the share capital of the Company by CHF 8,719.50 and by 87,195 shares up to CHF 517,418.80 and 5,174,188 shares with a nominal value of CHF 0.10 each at the Commercial Register in the Canton of Zurich. This increase is a consequence of the exercised options by employees in 2006.

In the course of the first three months 2007, 27,930 options have been exercised by employees and consultants, which resulted in an additional capital increase as of March 31, 2007 by CHF 2,793.00 and by 27,930 shares with a nominal value of CHF 0.10 each.

The total net proceeds (exercise price times number of options exercised) for the issuance of share capital in the first three months of 2007 amounted to CHF 1.3 million.

4) Segment and geographic information

Primary reporting format – business segment

The Group operates in one segment focusing on the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The Group's executive board reviews the profit or loss of the Group on an aggregated basis and manages the operations of the Group as a single operating segment. The Group currently derives its research and collaboration revenues from research and development collaborations with third parties.

Secondary reporting format – geographical segment

Research and collaboration revenues are attributable to individual countries and are based on the location of the customer, while the long-term assets and the liabilities are based on the location of the Group. All operating costs including research and development, sales and marketing, general and administrative, other operating income and expenses are generated in Switzerland. Management does not allocate the expenses to the individual countries where the company generated revenues.

The Group's geographic information is as follows:

in TCHF	January 1 – March 31, 2007				January 1 – March 31, 2006			
	CH	USA	Other	Total	CH	USA	Other	Total
Research and collaboration revenue	187	10	–	197	50	113	–	163
Segment result	187	10	–	197	50	113	–	163
Unallocated expenses				(8,758)				(8,759)
Operating loss				(8,561)				(8,596)
Financial income/(expenses), net				(146)				176
Deferred tax income convertible bond				2,992				–
Net loss				(5,715)				(8,420)
Other information				March 31, 2007				March 31, 2006
Assets				118,702				76,294
Liabilities				(67,794)				(8,508)
				January 1 – March 31, 2007				January 1 – March 31, 2006
Capital expenditure				337				567
Depreciation				703				689

5) Earnings/(Loss) per share

Basic and diluted net loss per share have been computed based upon the weighted average number of common shares outstanding. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase, warrants, and convertible securities. Neither outstanding options to purchase shares of common stock nor shares resulting from the conversion right of the bond holders were included in the computation of the dilutive net loss per share as the effect would have been anti-dilutive.

6) Share option plans

The Group regularly grants share options to employees. Usually the share options are equity-settled; one plan is cash-settled. The fair value of the options is determined at the grant date based on the market price using the Black-Scholes Model.

In November 2006, the board of directors approved a new share option plan ("SOP 2007"), according to which a total of 83,217 options were granted on January 8, 2007. Each option entitles the holder to purchase one share of the Company within five years after the grant date. Options can only be exercised after a cliff vesting period of two years. In the case of a change of control the options become exercisable. The exercise price is CHF 117.83, corresponding to the average closing price of the shares during the first three trading days in the year 2007. Management is convinced this represents the best estimate of the fair value of the underlying common stock. This option plan is classified as equity settled.

For these share options the following assumptions were used applying the Black-Scholes Option Pricing Model:

Share option conditions and assumptions	SOP 2007
Nature of arrangement	Grant of share options
Grant date	08.01.2007
Number of options granted	83,217
Exercise price (CHF)	117.83
Share price at date of grant (CHF)	118.00
Contractual life (years)	5.0
Vesting period (years)	2.0
Settlement	Equity
Expected volatility (%)	39.5
Expected option life at grant date (years)	3.5
Risk-free interest rate p.a. (%)	2.7
Expected dividend	zero
Estimated fair value at grant date (CHF)	38.06
Expiry date	07.01.2012
Valuation model	Black-Scholes

For all share options granted the Group expensed TCHF 1,086 and TCHF 722 for the first three months of 2007 and 2006, respectively.

7) Financial assets and liabilities

In the first three months of 2007, fixed-term time deposits in the amount of total CHF 13 million were paid back to the Group and have been reinvested together with the proceeds of the convertible bond according to the Group's financial plan.

End of March 2007 the Company redeemed early its outstanding loan of CHF 1.1 million.

8) Property and equipment

In the first three months of 2007, the Group invested TCHF 337 into property and equipment.

9) Real estate inventories

Three prepurchase contracts for properties in Belp have been executed in the first quarter 2007. Net proceeds amounted to CHF 2.4 million and a profit of CHF 1.1 million was reported as "Other income".

10) Long-term liabilities

In February 2007 the Company issued a 2.875% p.a. convertible bond with a nominal value of CHF 70 million. The bond matures in 5 years on February 20, 2012, and is convertible into the Company's shares at a conversion price of CHF 175. The values of the liability component and the equity conversion component were determined at issuance of the bond.

The fair value of the liability component, included in long-term liabilities, was calculated using a market interest rate for an equivalent non-convertible bond. The residual amount, representing the value of the equity conversion option, is included in shareholders' equity.

Transaction costs associated with the issuance have been allocated proportionately to the liability and equity components.

The convertible bond recognized in the balance sheet is calculated as follows:		TCHF
Nominal value of convertible bond issued in February 2007		70,000
Equity component		(11,788)
Transaction costs allocated to liability component		(1,811)
Liability component on initial recognition		56,401
Interest expense		454
Interest paid		-
Liability component at March 31, 2007		56,855

The fair value of the liability component of the convertible bond at March 31, 2007, is as high as the above mentioned carrying amount due to insignificantly changed interest rate compared to the issue date.

Interest expense of TCHF 454 for the convertible bond has been recognized in financial expense for the first quarter of 2007.

In conjunction with the issuance of the convertible bond, a deferred tax liability of CHF 3.0 million was recorded resulting from the initial recognition of the equity component of the convertible bond separately from the liability. This deferred tax liability was charged to equity. A deferred tax asset arising from net loss carryforwards was recorded in the same amount as the group had sufficient unused tax losses which could be utilized against those taxable temporary differences. As the deferred tax asset and liability relate to the same taxation authority and the same taxable entity, they were netted in the balance sheet. The recognition of the deferred tax asset has been recorded in "Deferred tax income" in the income statement.

Disclaimer

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this Quarterly Report, including but not limited to, statements, estimates and projections of future trends and of the anticipated future performance of Cytos Biotechnology AG and its subsidiaries (together “the Group”) constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievement of the Group, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. The forward-looking statements are based on the Group’s current beliefs and assumptions regarding a large number of factors affecting its business. Such beliefs and assumptions are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Group. There can be no assurance that: (i) the Group has correctly measured or identified all of the factors affecting its business or the extent of their likely impact, (ii) the publicly available information with respect to these factors on which the Group’s analysis is based is complete or accurate, (iii) the Group’s analysis is correct or (iv) the Group’s strategy, which is based in part on this analysis, will be successful. Factors which affect the Group’s business include, but are not limited to, (i) general market, governmental and regulatory trends, (ii) competitive pressures, (iii) technological developments, (iv) effectiveness and safety of the Group’s technology and therapeutics, (v) uncertainty regarding outcome of clinical trials and regulatory approval process, (vi) management changes, (vii) changes in the market in which the Group operates and (viii) changes in the financial position or credit-worthiness of the Group’s customers and partners.

Shareholder Information

Stock exchange listing at SWX Swiss Exchange

Registered shares: Swiss Security No.: 1 102 521, (SWX:CYTN)
Convertible bond 2012: Swiss Security No.: 2 906 073

Share register

Aktienregister Cytos Biotechnology AG
c/o Nimbus AG
Postfach, CH-8866 Ziegelbrücke

Capital structure

Number of registered shares (nominal value CHF 0.10)	5,202,118
Conditional capital	CHF 154,121
Authorized capital	CHF 200,000
Free float	92%

Contacts

Jakob Schlapbach
Chief Financial Officer
Phone: +41 44 733 46 46
E-mail: jakob.schlapbach@cytos.com

Claudine Blaser, PhD
Director Corporate Communications
Phone: +41 44 733 47 20
E-mail: claudine.blaser@cytos.com

Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a pipeline of different Immunodrug™ candidates in various disease areas, of which six are currently in clinical development. The Immunodrug™ candidates are developed both in-house and in collaboration with Novartis and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 129 employees. Cytos Biotechnology AG has been listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.

